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Purpose: To determine the expression of muscarinic receptor subtypes (mAChRs) in human and mouse scleral fibroblasts
(SFs), to investigate the mechanism that mediate the role mAChRs play in cell proliferation, and to explore the underlying
intracellular signaling pathways involved in mouse SFs with treatment of muscarinic agents.
Methods: Reverse transcription polymerase chain reaction (RT-PCR) was used to detect mRNA expression of mAChRs
in the human and mouse sclera. Western blot analysis and immunocytochemistry were used to detect proteins of mAChRs
in the cultured SFs. An immunohistochemical study was used to further detect the presence of mAChR proteins in frozen
scleral sections. BrdU (5-bromo-2-deoxyuridine ) cell proliferation assay was performed to measure DNA synthesis.
Enzyme linked immunosorbent assay (ELISA) was used to measure in vitro kinase activity for epidermal growth factor
receptor (EGF-R), fibroblast growth factor (FGF-2), transforming growth factor (TGF)-β1, and extracellular signal-
regulated kinase (ERK)1/2. Expressions of epidermal growth factor-receptor (EGF-R); protein kinase C (PKC); Proline-
rich tyrosine kinase 2 (Pyk-2), v-raf murine sarcoma viral oncogene homolog B1 (B-Raf), Rat Sarcoma (Ras), c-Jun N-
terminal kinases (JNK1/2), and ERK1/2 were detected by immunoblot.
Results: mAChR for subtypes M1-M5 were detected in both mouse and human SFs by protein, cellular, and mRNA
analysis.  EGF-R,  PKC,  Pyk-2,  B-Raf,  Ras,  JNK1/2,  and  ERK1/2  were  activated  after  treatment  by  agonists  and
antagonists,  indicated  by  changes  in  phosphorylation  of  these  proteins.  Atropine  abolished  the  carbachol-induced
activation of SF cell proliferation in a concentration-dependent manner. Carbachol also activated p42/44 mitogen-activated
protein kinase (MAPK) and Ras in a time-dependent manner. Muscarinic agents also modulated fibroblast growth factor
expression in these cells.
Conclusions: This study confirms the presence and functional role of all five mAChRs in human and mouse SFs. These
results show that proliferative responses of SFs to muscarinic receptor stimulation are mediated via the activation of the
classical MEK-ERK-MAPK cascade.
Myopia is a common problem in Asia [1,2], and the
prevalence  of  myopia  is  increasing  worldwide.  It  is  a
socioeconomic  problem,  and  high  myopia,  which  is  sight
threatening,  is  becoming  more  common  [3].  In  Taiwan,
myopia is considered a leading cause of blindness due to the
number of people with high myopia. Therefore, preventing
the progression of myopia is an active area of investigation.
Atropine, a pan muscarinic antagonist [4,5], and pirenzepine,
an  antagonist  more  specific  for  M1  [6],  have  been  found
effective in clinical trials with children in preventing myopia
progression. These two drugs have also been tested in studies
using animal models of myopia [7,8] and were found to block
axial elongation during the development of form-deprivation
myopia. Cellular signals acting on the main cell type of the
sclera, the fibroblast, may direct the growth process resulting
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in myopia. As muscarinic antagonists inhibit scleral growth
in children, the focus has been on muscarinic receptors.
By  understanding  the  specific  pharmacological  and
molecular mechanisms of the action of muscarinic antagonists
on  the  individual  muscarinic  receptors,  insights  into  the
molecular  signaling  pathway  in  axial  elongation  may  be
developed  [9].  Another  outcome  of  this  approach  is  the
development of specific blockers overcoming some of the side
effect  issues  associated  with  atropine,  a  pan  muscarinic
antagonist. Recently, we have developed a mouse model of
experimental myopia, and we demonstrated that the observed
axial elongation was due to growth of the posterior chamber
of the eye [10].
Many studies have reported that the muscarinic receptors
have important roles in the nervous system [11]. However,
recent studies have suggested that muscarinic receptors are
widely expressed in non-neuronal cells such as muscle fibers
and  epithelial,  endothelial,  and  immune  cells  [12,13].
Muscarinic  acetylcholine  receptors  are  widely  distributed
within the eye [14], once again making the identification of
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1277the  site  of  action  difficult.  Muscarinic  toxins  from  green
mamba venom modulate the proliferative actions of mAChRs
in mouse and human scleral fibroblasts [15]. The site of action
of the muscarinic cholinergic antagonists in human myopia is
not well known, although effects on the retina [16] and the
sclera [17] have been considered.
Since mAChRs are known to transactivate growth factor
receptors [18], the action of muscarinic antagonists may also
be  mediated  indirectly  through  receptor  tyrosine  kinases,
which  could  then  be  distributed  throughout  signaling
pathways within the sclera fibroblast. Tyrosine kinases are
important components of signaling pathways that couple cell
surface receptors to the regulation of cellular activities such
as gene expression, proliferation, and ion channel modulation.
Studies  show  that  growth  factors,  cytokines,  integrins,
antigens,  and  G  protein  coupled  receptors  (GPCRs)  also
utilize  tyrosine  kinases  to  transduce  intracellular  signals
[19-22].  In  fact,  GPCRs  are  the  most  frequent  targets  of
pharmacological therapies.
A recent study has demonstrated that multiple mAChRs
occur in mammals including humans, and the distribution of
these receptors is tissue specific [17]. In human ocular tissues,
the M3 receptor is the main mAChR in the cornea, iris, ciliary
body, and epithelium of the crystalline lens [23,24]. The M3
and M4 receptors are the main mAChRs in the retina [16],
M1-M4 are the main ones in lung fibroblasts [25], and M1,
M3, and M5 are functional in human labial salivary glands
[26]. The biology of the subtypes of mAChRs have not been
explored in detail in the eye, but at both mRNA and protein
levels, all five mAChRs were detected in the human sclera
[27], tree shrew sclera [28], guinea pig sclera [29], mouse
sclera  [30],  monkey’s  eyelid  conjunctival  epithelial  cells,
meibomian glands and supra-basal layers of the skin [31].
However, the functional significance of cholinergic receptors
in scleral fibroblasts (SFs) remains to be studied in detail.
Thus, we suggest that mAChRs regulation are necessary
for the growth of the sclera in experimental myopia. It is
shown here that mAChRs mediate the proliferation of human
and mouse SFs, which in turn may have a role in scleral
remodeling.  The  aim  of  our  study  was  to  determine  the
expression  of  mAChRs  in  human  and  mouse  SFs  and  to
investigate  whether  mAChRs  can  mediate  SF  cell
proliferation.
METHODS
Human sclera: Human scleral tissues (n=19) harvested within
24 h from cadaver eyes were provided by the Singapore Eye
Bank. The protocol was approved by the Institutional Review
Board of the Singapore Eye Research Institute and complied
with the tenets of the Declaration of Helsinki.
Animals:  BALB/c  mice  (n=102)  were  obtained  from  the
animal holding unit of the National University of Singapore.
All animals were housed in standard mouse cages at 25 °C on
a schedule of 12 h:12 h of light on and off with mouse pellet
and water available ad libitum, and the water was regularly
changed.  Approval  was  obtained  from  the  SingHealth
IACUC, and all procedures performed in this study were in
accordance with the Guide for the Care and Use of Laboratory
Animals  and  ARVO  recommendations  for  animal
experimentation.
Culture of human and mouse scleral fibroblast cells: Scleral
rims from donor human cadaver eyes (n=16) and eight-week-
old mouse sclera (n=150, 10 sclera/batch) from post-mortem
eyes were obtained. The whole sclera was dissected very
carefully and washed with cold phosphate buffered saline
(PBS) three times. The human scleral tissue was cut into 2
mm×2 mm pieces, and the mouse scleral tissue was cut into 1
mm×1  mm  pieces.  Scleral  tissues  were  dispersed  by
incubating  with  0.25%  trypsin/0.5  mM  EDTA  (Sigma,
Hamburg, Germany) for 5 min at 37 °C. The tissues were
placed  on  60  mm×15  mm  cell  culture  dishes  (Greiner,
Dresden, Germany) with a thin layer of Dulbecco’s modified
Eagle’s medium (DMEM; Sigma) supplemented with 10%
fetal bovine serum (FBS; Gibco BRL, San Francisco, CA), 50
U/ml penicillin, and 50 µg/ml streptomycin and amphotericin
B (Sigma). Cells were grown in a humidified atmosphere of
5% CO2 at 37 °C. After initial cell outgrowth from the explants
was observed, the volume of the medium was increased. The
cultures were passaged on reaching 80% confluence. All cells
used in experiments were between passages 1 and 2.
Cell proliferation assay: SFs were passaged from human and
mouse scleral tissues and used between passages 1 and 2. Cell
proliferation  was  assessed  by  measuring  5-bromo-2-
deoxyuridine (BrdU) incorporation during DNA synthesis in
proliferating cells (Oncogene, Cambridge, MA). For the cell
proliferation assay, 100 μl of passaged SFs (1×105 cells/ml)
were seeded into 96 well plates containing DMEM with 10%
FBS. Cells were allowed to attach to the substratum for 24 h.
The  following  day,  the  medium  was  replaced  with  fresh
DMEM  containing  10  µM  BrdU  (Oncogene)  to  be
incorporated into newly synthesized DNA. Cells were then
treated  with  experimental  concentrations  of  the  pan
muscarinic receptor agonist, carbachol (Sigma); muscarinic
toxin-1  (MT-1,  a  well  characterized  M1-specific  agonist
derived  from  snake  venom;  Peptides  International  Inc.,
Louisville,  KY);  or  the  pan  receptor  antagonist,  atropine
(Sigma);  or  M1  selective  antagonist,  pirenzepine  (Sigma);
muscarinic  toxin-7  (MT-7,  M1  specific  antagonist  derived
from  snake  venom;  Peptides  International  Inc.);  M2/M4
receptor antagonist, himbacine; or the M3 receptor antagonist,
4-(diphenylacetoxy-N-methyl  piperidine)  methiodide  (4-
DAMP).  To  study  the  combined  effect  of  atropine  and
carbachol, SFs were pre-treated with atropine (0.1–100 µM)
3 h before being incubated with equimolar carbachol.
After  24  h  of  incubation,  the  culture  medium  was
removed, cells were fixed and permeabilized, and the DNA
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BrdU.  Anti-BrdU  antibody  was  added  to  the  wells  and
incubated for 1 h at room temperature. Unbound antibodies
were washed away, and horseradish peroxidase-conjugated
goat-anti mouse was added. A substrate solution was added
to each well, resulting in a color change proportional to the
amount of DNA synthesis in the cells. The color reaction was
stopped,  and  the  optical  density  was  determined  using  a
Spectrafluor Plus microplate reader (TECAN, Durham, NC),
set to 450 nm-595 nm.
Immunohistochemistry  and  immunocytochemistry:  The
whole mouse eye (two months old, n=3) and human sclera
(n=3) was embedded in Optimal Cutting Temperature (OCT)
compound at −20 °C for 1 h. Prepared tissue blocks were
sectioned with a cryostat at 5 microns and collected on clean
polysine™  glass  slides  (Thermo  Fisher  Scientific,
Newington, CT). Sections were air dried at room temperature
(RT) for 1 h and fixed with 4% paraformaldehyde for 10 min.
After washing three times for 5 min each with 1X PBS and
then adding 4% goat serum diluted with 1X PBS as a blocking
buffer, slides were covered and incubated for 1 h at RT in a
humidified chamber. After rinsing with 1X PBS, a specific
primary antibody for M1-M5 (Biogenesis, Poole, England)
was  diluted  with  2%  goat  serum  (1:100)  and  incubated
overnight at 4 °C in a humid chamber. After washing three
times for 10 min each with 1X PBS, fluorescein-labeled goat
anti-rabbit secondary antibody (1:200; Sigma) was applied
and incubated for 90 min at RT. After washing and air drying,
slides were mounted with an antifade medium containing
DAPI (4, 6-diamidino-2-phenylindole; Vectashield; Vector
Laboratories,  Burlingame,  CA)  to  visualize  nuclei.  For
negative controls, primary antibodies were omitted.
In parallel, mouse and human SFs were cultured on sterile
chamber slides. Cells were washed with PBS and fixed with
ice-cold methanol:acetone (1:1) at −20 °C for 10 min and air-
dried. Cells were permeabilized with 0.5% Triton X-100 in
PBS for 2 min at RT. Non-specific sites were blocked with
1% bovine serum albumin (BSA), 0.3% Triton X-100, and
PBS for 30 min at RT for the cells. The cells were then
processed and stained as described above. The cells were
mounted  on  coverslips  with  Flurosave  mounting  medium
(Calbiochem, San Diego, CA). A fluorescence microscope
(Axioplan  2;  Carl  Zeiss  Meditec  GmbH,  Oberkochen,
Germany)  was  used  to  examine  the  slides  and  images
captured. Experiments were repeated in triplicate from three
different samples.
RNA isolation and RT–PCR: The mouse globe (n=50, 10
sclera/batch) was washed with a buffered saline solution to
remove traces of blood and other material. The sclera behind
the optic nerve head was dissected from each eye. The whole
retina including the retinal pigment epithelium (RPE) was
stripped off from the sclera, and choroid was removed with a
No. 10 scalpel blade. The whole sclera was then immediately
frozen in liquid nitrogen.
Total RNA was extracted from human and mouse scleral
tissues  (TRIzol  reagent;  Invitrogen-Gibco,  Carlsbad,  CA).
Genomic DNA was removed by digestion with DNase I (Amp
Grade; Invitrogen-Gibco) for 15 min at RT. One microgram
of total RNA was reverse-transcribed with random hexamers
by using a first-strand cDNA synthesis kit (Invitrogen-Gibco).
To standardize and evaluate scleral gene expression, aliquots
of the same cDNA preparation were used as templates in all
polymerase  chain  reactions  (PCR)  reactions.  PCR
amplification  (PTC-200  Peltier  Thermal  Cycler;  MJ
Research,  Ramsey,  MN)  was  performed  using  Taq  DNA
polymerase  (Promega,  Madison,  WI).  Each  reaction
confirmed that the PCR products were not saturated. The
primers for muscarinic receptors were constructed with the
Primer  Express  Software  version  1.0  (PE  Applied
Biosystems,  Foster  City,  CA)  using  a  mouse  and  human
specific acetylcholine muscarinic receptor subtypes sequence
(Table 1 and Table 2, respectively). Total RNA extracted from
the  mouse  brain  was  used  as  a  positive  control.  PCR
amplification  of  β-actin  was  performed  in  parallel  as  an
internal control to detect genomic DNA contamination. The
amplified products were analyzed by electrophoresis on 1.2%
and  2.5%  agarose-TAE  gels  (human  and  mouse  sclera,
respectively) and photographed under ultraviolet (UV) light.
All experiments were done in triplicate.
Relative and absolute quantitative real-time PCR: Real-time
PCR primers for transcripts of M1-M5 were purchased from
Applied Biosystems Inc. (Taqman Gene Expression System;
ABI, Foster City, CA), and Quantum RNA classic II 18S
Internal  Standard  (Ambion,  Austin,  TX)  was  used  as  an
endogenous control. The 18S primer-competimer ratio of 1:4
was used in all experiments. Real-time PCR reactions were
performed on a sequence detection system (Prism 7700; ABI)
with 500 ng of total cDNA per reaction in a final volume of
25 µl. The CT (threshold cycle) of each reaction was obtained
by using a constant threshold with the 18S rRNA used as an
internal  control.  ∆CT  was  calculated  by  subtracting  the
average CT of 18S rRNA from the average CT of the target
gene. All experiments were performed in triplicate. This was
repeated  with  five  different  batches  of  samples.  The
conditions for the PCR were as follows: 55 °C for 2 min, 95 °C
for 10 min and 40 cycles each of 95 °C for 30 s, 60 °C for 30
s, and 72 °C for 2 min. The comparative quantification values
were obtained from the threshold cycle (CT) number at which
the increase in signal was associated with an exponential
growth  of  PCR  products  and  this  was  detected  in  SDS
(Satellite  Data  System)  software  in  ABI  PRISM®  7700
Sequence Detection System. The PCRs were performed (n=5)
for each sample-primer set, and the mean of the experiments
was used as the relative quantification value. For all M1-M5
probes,  the  ABI-confirmed  amplification  specificity  of
TaqMan probes and the reaction products were separated on
3% agarose gel, stained with ethidium bromide for visual
confirmation of PCR products, and sequenced.
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1279Data  analysis  by  comparative  CT  method:  The  CT  value
represented the PCR cycle at which an increase in reporter
fluorescence  (∆Rn)  above  the  line  of  the  optimal  value
(optimal  ∆Rn)  was  first  detected.  The  calculation  for  the
comparative  CT  (∆∆CT)  method  was  previously  described
[32]. 18S rRNA was used as an endogenous internal control.
The average CT value of all muscarinic receptor genes and 18S
rRNA was calculated from each experiment of a triplicate, and
this was used for all five samples. Finally, the mean CT value
was calculated from the five average CT values. The ∆CT value
was determined by subtracting the corresponding mean 18S
rRNA CT value from the mean of the M1-M5 CT value. The
standard deviation of the difference was calculated from the
standard  deviations  of  the  gene  of  interest  and  the
corresponding  18S  rRNA  values.  The  ∆∆CT  value  was
obtained by subtracting the ∆CT calibrator value. This was the
subtraction of an arbitrary constant so the standard deviation
of the ∆∆CT was similar to the standard deviation of the ∆CT
value. The expression level of each gene in the mouse brain
was used for calibration. ∆∆CT of the scleral sample was
calculated by subtracting the ∆CT of the mouse brain from
∆CT  of  the  scleral  sample.  The  relative  change  of  scleral
samples compared with brain samples was determined as 2-
∆∆CT.  Statistical  analysis  was  performed  by  ANOVA.  The
expression levels of the genes for M1–M5 in the sclera were
compared by the Fisher LSD (Least Significant Difference)
test. A probability level of p<0.05 was considered statistically
significant.
Phospho-p42/44  MAPK  activation  assay:  Mouse  SF  cell
lysate was exposed to atropine and carbachol at 0, 0.1, 1, 10,
and 100 µM for 0.5 h. Phospho-p42/44 mitogen-activated
protein kinase (MAPK) assay kit were purchased from Assay
Design (Ann Arbor, MI), and all procedures were conducted
according to the instructions provided by the company. A
monoclonal  antibody  specific  for  phospho-p42/44  MAPK
was pre-coated onto a 96 well microtiter plate. Standards and
samples were added into the wells, and p42/44 MAPK became
bound to the immobilized antibody. Proteins were removed
by  washing,  and  an  enzyme-linked  monoclonal  antibody
specific for p42/44 MAPK was added to the wells. Washed
again to remove any unbound antibody-enzyme reagent and
the calorimetric, a substrate solution was added to the wells.
TABLE 1. PRIMER SEQUENCES AND SIZES OF MOUSE PCR PRODUCTS.
Gene                                     Primers                                                                                                                 Size
M1 F: 5′-TCCCTCACATCCTCCGAAGGTG-3′ 139 bp
R: 5′-CTTTCTTGGTGGGCCTCTTGACTG-3′
M2 F: 5′-CTGGAGCACAACAAGATCCAGAAT-3′ 69 bp
R: 5′-CCCCCTGAACGCAGTTTTCAGT - 3′
M3 F: 5′-GCAAGACCTCTGACACCAACT-3′ 91 bp
R: 5′-AGCAAACCTCTTAGCCAGCG-3′
M4 F: 5′-CGGCTACTGGCTCTGCTACGTCAA-3′ 122 bp
R: 5′-CTGTGCCGATGTTCCGATACTGG-3′
M5 F: 5′-TAGCATGGCTGGTCTCCTTCA-3′ 76 bp
R: 5′-CGCTTCCCGACCAAGTACTG-3′
TABLE 2. PRIMER SEQUENCES AND SIZES OF HUMAN PCR PRODUCTS.
Gene                                     Primers                                                                                                                 Size
M1 F: 5′-CAGGCAACCTGCTGGTACTC-3′ 538 bp
R: 5′-CAGGCAACCTGCTGGTACTC-3′
M2 F: 5′-CTCCTCTAACAATAGCCTGG-3′ 654 bp
R: 5′-GGCTCCTTCTTGTCCTTCTT-3′
M3 F: 5′-GGACAGAGGCAGAGACAGAA-3′ 560 bp
R: 5′-GAAGGACAGAGGTAGAGTGG-3′
M4 F: 5′-ATCGCTATGAGACGGTGGAA-3′ 503 bp
R: 5′-GTTGGACAGGAACTGGATGA-3′
M5 F: 5′-ACCACAATGCAACCACCGTC-3′ 752 bp
R: 5′-ACAGCGCAAGCAGGATCTGA-3′
β-actin F: 5′-CACTCTTCCAGCCTTCCTTC-3′ 314 bp
R: 5′-CTCGTCATACTCCTGCTTGC-3′
The β-actin PCR primer pair was selected to span a 206 bp intron [61].
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1280Color was developed in proportion to the amount of p42/44
MAPK bound in the initial step. The intensity of the color was
measured at 450 nm with an enzyme-linked immunosorbent
assay (ELISA) reader (TECAN, Durham, NC) to determine
the levels of phosphorylated p42/44 MAPK proteins.
Western blotting-protein expression of mAChRs: The nearly
confluent mouse and human SFs were homogenized in ice-
cold  radio  immunoprecipitation  assay  (RIPA)  buffer
containing proteinase inhibitors (10 mM Tris-HCl [pH 7.4],
containing 150 mM NaCl, 1% deoxycholic acid, 1% Triton
X-100,  0.1%  SDS,  1  mM  EDTA,  10  mg/ml
phenylmethylsulfonyl fluoride, 5 U/ml aprotinin, and 100 nM
sodium orthovanadate) and phosphatase inhibitors (Pierce,
Rockford,  IL).  After  homogenization,  the  samples  were
centrifuged  at  14,000x  g  for  10  min  at  4  °C,  and  the
supernatants were used as total cell lysates.
Total protein concentration was determined using a direct
colorimetric (DC) protein assay reagent (Bio-Rad, Hercules,
Figure 1. Immunohistochemistry of muscarinic receptor subtypes in early passages of cultured human and mouse scleral fibroblasts. A is the
image of the early passage of cultured human fibroblasts, and B is the image of the early passage of mouse scleral fibroblasts. Subtype selective
antibodies bound to cultured cells demonstrated the presence of the muscarinic receptors M1-M5 (shown in green). When primary antibodies
were omitted, no binding was observed (negative control). The M1-M5 receptors were localized to the cell membrane as well as to the cytoplasm.
Magnification, 200X. All experiments were performed in triplicate.
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1281CA).  Theses  proteins  were  used  to  detect  the  muscarinic
receptors in both human and mouse SF using immunoblot.
Proteins in the supernatant were separated by SDS–PAGE,
transferred to nitrocellulose membranes, blocked in 5% BSA
in TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, and
0.05% Tween-20) for 2 h at RT, and incubated with the same
anti-muscarinic  receptor  antibodies  described  earlier  at  a
dilution of 1:1000 to detect the mAChRs proteins.
Analysis of Erk1/2 and Ras phosphorylation by carbachol and
FGF-2 on mouse SF: The mouse SF cells were cultured in a
Figure 2. Immunohistochemistry of mAChR subtypes from human and Balb/c mouse. A shows the image of the human mAChR subtypes, and
B illustrates the image of the Balb/c mouse mAChR subtypes. Subtype selective antibodies bound to scleral fibroblasts (arrowheads)
demonstrates the presence of M1-M5 receptors (shown in green and nucleus shown in blue; stains with DAPI) at magnification 400X. When
secondary FITC-labeled antibody was used without the primary antibody, no significant binding was observed (-ve cont means negative
control). Arrow indicates scleral fibroblast. Scale bar=50 μm. Inset in B: enlarged image of fibroblast. All experiments were done in triplicate.
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1282serum-containing  medium  in  six  wells  (2×105 cells/well).
Cultured mouse SFs were starved for 24 hours and then was
incubated with 50 mg/ml carbachol or 50 ng/ml FGF-2 for 0.5,
1, 2, 6 h and over night to detect the optimal time required for
MAPK (ERK1/2) and Ras phosphorylation in these cells. For
detection, western blot was performed as described below.
Analysis of phosphorylation by muscarinic agents in mouse
SF: The mouse SF cells were cultured in a serum-containing
medium  in  six  wells  (2×105  cells/well).  From  the  earlier
analysis, we found that 30 min was the optimal time to detect
the  ERK1/2  phosphorylation.  Hence,  we  have  treated  the
mouse SFs with freshly prepared atropine, pirenzepine, and
carbachol at a concentration of 50 µM and MT-1 and MT-7
at a concentration of 0.5 µM for 30 min to determine the
signaling phosphorylation of EGF-R, PKC, Pyk2, B-Raf, Ras,
JNK1/2 and ERK1/2 proteins with the effect of muscarinic
agents. Protein extraction and electrophoresis were performed
as described above.
For detection, the membrane was incubated with anti-Ras
clone  RAS10,  phospho-EGF-R,  PKC,  Pyk2,  B-Raf,  Ras,
JNK1/2, and ERK1/2 antibodies at the dilution of 1:1000
according  to  the  instructions  provided  by  the  company
(Millipore, Billerica, MA) for 2 h at RT, and β-tubulin was
used as a loading control and was incubated for 1 h at RT.
All three experiments’ membranes were washed three
times in TBST and incubated with HRP-conjugated secondary
antibody  (Chemicon  International,  Temecula,  CA)  at  a
dilution of 1:2500 for 1 h at RT. Immunoreactive bands were
visualized using the enhanced chemiluminescence method
(GE Healthcare, Buckinghamshire, UK). The membrane was
wrapped in plastic and placed against X-ray film, exposed for
an appropriate length of time (30 s to 5 min), and developed
(Kodak, Rockford, IL).
Growth factor receptors ELISA: Mouse SF cell lysate was
exposed to atropine and carbachol at concentrations of 0, 0.1,
1, 10, and 100 µM for 24 h. Cellular EGF, fibroblast growth
factor-2 (FGF-2), and transforming growth factor (TGF)-β1
receptors in the presence of muscarinic agents was quantified
by an ELISA. Equal amounts of samples or standards were
added  to  each  well  (anti-EGF-R,  -FGF-2,  and  -TGF-β1
antibody pre-coated) and incubated for 2 h at RT. The wells
were aspirated and washed with PBST. Anti-EGF, -FGF-2
Figure 3. Gene expression of muscarinic
receptor  subtypes  A:  RT–PCR
identified cDNA for M1-M5 in human
scleral fibroblasts. Lane 1: DNA ladder;
lane 2: M1; lane 3: M2; lane 4: M3; lane 5:
M4; lane 6: M5. PCR products of the
expected sizes were as follows: M1, 538
bp; M2, 654 bp; M3, 560 bp; M4, 503 bp;
and  M5,  752  bp.  The  identity  of  the
products was confirmed by sequencing.
B: RT–PCR identified cDNA for M1-
M5 in mouse scleral fibroblasts. Lane 1:
DNA ladder; lane 2: mouse brain as a
positive control; lane 3: mouse sclera.
PCR products of the expected sizes were
as follows: M1, 139 bp; M2, 69 bp; M3,
91 bp; M4, 122 bp; and M5, 76 bp. C: β-
actin as internal control, 314 bp for all
cDNAs used. Lane 1: DNA ladder; lane
2: mouse brain; lane 3: human sclera;
lane 4: mouse sclera. D: Water was used
as  a  negative  control.  Lane  1:  DNA
ladder; lane 2: M1; lane 3: M2; lane 4:
M3; lane 5: M4; lane 6: M5. Identity of
the  products  was  confirmed  by
sequencing  (see  Methods  for  detailed
information).
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1283(Chemicon  International  Inc.),  and  -TGF-β1  (Amersham
Pharmacia  Biotech,  Buckinghamshire,  UK)  mouse  IgG
conjugated with horse-radish peroxidase was added to the
respective  wells  and  incubated  for  2  h  at  RT.  Substrate
solution was added to each well, resulting in a color change
proportional to the amount of EGF-R, FGF-2, and TGF-β1
present in the samples. Samples were allowed to develop color
for 20 min at RT. Adding stop solution stopped the reaction,
and the optical density was determined within 30 min using
Spectrafluor  Plus  microplate  reader  (TECAN)  at  dual
wavelengths  of  450  nm  and  620  nm.  Quantification  was
achieved by the construction of a standard curve using the
known concentration of EGF, FGF-2, and TGF-β1 receptors.
Data analysis: Statistical comparisons between experimental
groups  were  conducted  using  Student’s  t-test  or  one-way
ANOVA  (Statistica  6.0;  SPSS,  Chicago,  IL)  followed  by
Tukey post hoc test. A significance level of p<0.05 was used.
Data  are  presented  as  means±SEM  (standard  error  of  the
mean).
RESULTS
Cellular  expression  of  M1-M5:  Immunohistochemical
localization of muscarinic receptors M1-M5 was performed in
passage 2-cultured human and mouse scleral fibroblasts (SFs)
as well as scleral tissues. Positive immunostaining for all five
mAChR  subtypes  was  shown  in  the  cultured  human  and
mouse SFs (Figure 1A,B, respectively) as well as in human
and mouse scleral tissues (Figure 2A,B, respectively). The
M1-M5 receptors were localized to the cell membrane as well
as to the cytoplasm. No immunostaining was observed in the
negative  controls.  Thus,  all  five  receptor  types  were
represented in mouse and human scleral fibroblasts at passage
2 as well as in the mouse scleral tissue.
Figure 4. Muscarinic receptor sub-types transcript levels in mouse
sclera. The bar graph compares the relative gene expression of mouse
scleral muscarinic receptor subtypes to the corresponding mouse
brain  mRNA  level  (range)  after  normalization  with  18S  rRNA
internal standard. The mRNA level of M1, M3, and M4 in mouse sclera
was less than in the mouse brain. However, the mRNA level of M2
and M5 was abundant in the mouse sclera.
Gene  expression  of  muscarinic  receptor  subtypes:  RNA
(1 µg) sample from each collected tissue (n=10 sclera) was
separated on a 1.2% agarose gel to determine the RNA purity
before further analysis. By conventional PCR, expression of
all five mAChRs was detected in human and mouse sclera
(Figure 3A,B, respectively). The identity of each PCR product
was  further  confirmed  by  sequencing.  Mouse  primer
sequences showed a high sequence identity to the NCBI Blast
mAChR subtypes of mouse sequences (M1 99%, M2 100%,
M3 100%, M4 100%, M5 100%). As none of the five mAChR
genes has introns, the PCR product from genomic DNA would
yield  the  same-sized  amplicons.  To  rule  out  possible
contamination by genomic DNA, we chose a pair of β-actin
primers at two adjacent exons that spanned a 206 bp intron on
cDNA derived from β-actin mRNA. The identification of a
single reverse transcription polymerase chain reaction (RT–
PCR) product of predicted size for β-actin mRNA rules out
contamination by genomic DNA. The β-actin primers were
designed to span a 206 bp intron, finding a single band of 314
bp verifies that genomic DNA was not present.
Figure  5.  Muscarinic  receptor  protein  expression.  A:
Immunoreactive bands corresponding to each muscarinic receptor
subtype in mouse scleral fibroblasts and their estimated molecular
weights are shown: ~58 kDa (M1), ~52 kDa (M2), ~52 kDa (M3),
~66 kDa (M4), and ~65 kDa (M5). Blots are representative data from
at least three independent experiments. B: Immunoreactive bands
corresponding to each muscarinic receptor subtypes in human scleral
fibroblasts  and  their  estimated  molecular  weights  are  shown:
~57 kDa (M1), ~52 kDa (M2), ~56 kDa (M3), ~58 kDa (M4), and
~51  kDa  (M5).  Blots  are  representative  data  from  at  least  three
independent experiments. Molecular standards (50-75 kDa) were run
on the same blot parallel with muscarinic receptor proteins. The
positions are shown in the left hand side.
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1284Quantitative  real-time  PCR  was  used  to  compare  the
relative abundance of the transcript of each mAChR in the
sclera.  These  levels  were  also  compared  to  M1-M5  gene
expression  in  the  mouse  brain  cerebellum.  Normalized
expression levels of M1, M3, and M4 were lower in the sclera
when  compared  to  the  levels  for  the  mouse  cerebellum
(p<0.001). However, the levels of M2 and M5 were greater in
the sclera when compared to the mouse cerebellum (p<0.05,
n=10 sclera from five mice; Figure 4).
Western blot analysis: Western blot analysis using SFs at
passage 3 was performed using human and mouse cells to
determine levels of protein expression of each muscarinic
receptor  subtype.  Figure  5  shows  that  major  bands
representing M1 (58 kDa), M2 (52 kDa), M3 (52 kDa), M4 (66
kDa),  and  M5  (65  kDa)  were  detected.  All  five  mAChR
proteins were expressed in both mouse (Figure 5A) and human
(Figure 5B) SFs.
Muscarinic  antagonists  inhibited  DNA  synthesis:  As
muscarinic receptors are often linked to proliferation, we used
this as an indicator of cell function of pharmacological control
exerted  through  mAChRs.  SFs  were  exposed  to  atropine,
pirenzepine, or MT-7 for 24 h using a range of concentrations.
Figure 6. Muscarinic agents and mouse
scleral fibroblast cell proliferation. A:
The  effect  of  muscarinic  agents  on
mouse  scleral  fibroblast  cell
proliferation is illustrated on the graph.
SFs  were  incubated  with  atropine,
pirenzepine, carbachol, himbacine, and
4-DAMP  at  0.1–100  μM  and  with
muscarinic toxin-7 (MT-7), muscarinic
toxin-1 (MT-1) at 0.1, 1, 2, 4 μM all for
24  h,  and  BrdU  incorporation  was
measured  by  ELISA.  Antagonists
significantly inhibited DNA synthesis in
a  dose-dependent  manner  (p<0.05,
ANOVA, n=4). In contrast, muscarinic
receptor agonists, carbachol and MT-1,
increased cell proliferation in a dose-
dependent  manner  (p<0.05,  ANOVA,
n=4).  Data  are  represented  as  mean
±SEM.  The  asterisk  indicates  p<0.05
versus  control  (Post  Hoc  Analysis;
Tukey Honest Significant Difference).
B: Effects of muscarinic agents on cell
proliferation  of  human  scleral
fibroblasts  are  shown.  Scleral
fibroblasts  were  incubated  with
atropine,  pirenzepine,  carbachol,  and
atropine/carbachol at 0.1–100 μM for 24
h,  and  BrdU  incorporation  was
measured  by  ELISA.  Antagonists
significantly inhibited DNA synthesis in
a  dose-dependent  manner  (p<0.05,
ANOVA, n=4). In contrast, muscarinic
receptor  agonist,  carbachol,  increased
cell  proliferation  in  a  dose-dependent
manner  (p<0.05,  ANOVA,  n=4).
Atropine was more effective at 10 and
100 μM than pirenzepine at all of the
concentrations. Data are represented as
mean±SEM.  The  asterisk  indicates
p<0.05  versus  control  (Post  Hoc
Analysis;  Tukey  Honest  Significant
Difference).
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1285By microscopic observation, cell morphology showed little
differences between treatment groups and control groups, and
viability as determined by the trypan blue exclusion assay
showed that there was no toxicity after 24 h incubation of the
cells  with  up  to  100  μM  of  atropine  (EC50=501.1  μm  or
0.5011 mM) and pirenzepine (EC50=7040 μm or 7.040 mM)
or 1 μM of MT-7. DNA synthesis, measured after 24 h using
a  BrdU  ELISA  assay,  was  inhibited  after  atropine,
pirenzepine,  and  MT-7  exposure  when  compared  with
untreated control SFs (p<0.05, n=4; Figure 6A,B). In addition,
when examining the competition between the agonists and
antagonists,  atropine,  pirenzepine,  and  MT-7  blocked  the
effect of the action of carbachol (EC50=177.827 mM) and
MT-1 (muscarinic agonist) when SFs were pre-treated (3 h)
with an equimolar amount of antagonists (Figure 7). MT-7,
which is selective for the M1, was almost as effective as
Figure  7.  Effect  of  muscarinic
antagonists in SF cell proliferation. Cell
proliferation of mouse sclera fibroblasts
were  pre-incubated  with  atropine,
pirenzepine at concentrations of 0.1, 1,
5, 10, and 100 μM, and MT-7 at 0.1, 1,
2,  4  μM  for  3  h  before  they  were
incubated with equimolar carbachol at
0.1–100 μM and MT-1 at 0.1, 1, 2, 4
μM. BrdU incorporation was measured
24 h later by ELISA. Cells were treated
together with antagonists and agonists.
The antagonists blocked the agonist’s
activation in a dose-dependent manner
(p<0.05, ANOVA, n=4). Data represent
mean±SEM.  The  asterisk  indicates
p<0.05  versus  control  (Post  Hoc
Analysis;  Tukey  Honest  Significant
Difference).
Figure  8.  The  activation  of  p42/44
MAPK  in  the  muscarinic  receptor-
mediated responses in mouse SFs was
analyzed  via  ELISA.  The  cells  were
exposed  to  atropine,  pirenzepine,  and
carbachol at concentrations of 0.1, 1, 10,
and 100 µM and to MT-7 and MT-1 at
concentrations of 0.001, 0.01, 0.1, and 1
M.  Phospho-p42/44  MAPK  was
activated in a dose-dependent manner
(p<0.05, n=4). Data are represented as
mean±SEM.
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1286atropine,  a  pan-muscarinic  blocker,  in  decreasing  BrdU
uptake.
Effect  of  muscarinic  agents  on  MAPK  activity:  From  the
preceding  data,  it  would  be  suggested  that  the  MAPK
pathways should be activated. We examined phosphorylation
of  p42/44  MAPK  in  mouse  SFs  following  exposure  to
atropine, pirenzepine, and carbachol at concentrations of 0.1,
1, 10, and 100 µM and to MT-7 and MT-1 at concentrations
of 0.001, 0.01, 0.1, and 1 µM using ELISA. Phospho-p42/44
MAPK was formed in a dose-dependent manner (Figure 8).
Phospho-p42/44  MAPK  decreased  with  the  muscarinic
antagonists and increased in response to the agonists (p<0.05,
n=4).
Immunoblot analysis: The muscarinic receptors have been
involved in trans-activation with tyrosine kinase receptors.
We examined several specific points in the pathway to provide
further  information  about  the  MAPK  pathway.  Phospho-
EGF-R,  -PKC,  -Pyk2,  -B-Raf,  -Ras,  -JNK1/2,  and  total/
phospho-Erk1/2 were expressed at protein levels in mouse
scleral fibroblasts following 30 min exposure to muscarinic
agents, and β-tubulin was used as the loading control (Figure
9).  The  antagonists  (atropine,  pirenzepine,  and  MT-7)
inhibited the formation of phospho-EGF-R, -PKC, -Pyk2, -B-
Raf, -Ras, -JNK1/2, and -ERK1/2. In the absence of treatment,
there was no effect on total Erk1/2, β-tubulin, or control. In
Figure 9. Effect of muscarinic agents on MAPK signaling proteins.
Phospho-EGF-R,  PKC,  Pyk2,  B-Raf,  Ras,  JNK1/2  and
ERK1/2activity was detected by immunoblot in the cultured mouse
SF cells after being treated with atropine, pirenzepine, and carbachol
at  a  concentration  of  50  µM  and  with  MT-7  and  MT-1  at  a
concentration of 0.5 µM all for 30 min. β-tubulin was used as a
loading control for all the treatment. Antagonists increased their
activation, and agonists reversed this.
contrast, in SFs that were treated with the agonists (carbachol
and MT-1), the activation of phospho-EGF-R, -PKC, -Pyk2,
-B-Raf, -Ras, -JNK1/2, and -ERK1/2 increased.
Carbachol-induced Ras and ERK1/2 phosphorylation: We
further demonstrated the carbachol-Induced Ras and ERK1/2
phosphorylation in mouse SFs to show the muscarinic agents
also had parallel effects on the appropriate signal transduction
pathways. As seen below, carbachol produced a time-and
dose-dependent  increase  in  Ras  and  MAPK/ERK
phosphorylation in SFs.
We examined the activation of Ras and p42/44 MAPK in
the  muscarinic  receptor-mediated  responses  in  SF  cells.
Stimulation with 50 mg/ml of carbachol resulted in increased
activity in Ras and p42/44 MAPK in a time-dependent manner
(Figure 10). Ras and p42/44 MAPK activation was initially
observed at 30 min with 50 mg/ml of carbachol stimulation
(p<0.05, n=4). As a comparison to the activation of p42/44
kinase  elicited  by  carbachol,  we  tested  fibroblast  growth
factor (FGF-2) at 50 ng/ml, which was also found to activate
Ras and p42/44 MAPK (Figure 11) with peak phosphorylation
at 30 min (p<0.05, n=4). At 2 h, the level of Ras and phospho-
Figure 10. Activation of ERK1/2 and Ras by 50 mg/ml carbachol in
cultured mouse scleral fibroblast cells. Cultured mouse SF cells were
serum starved for 24 h in DMEM and then incubated with 50 mg/ml
of carbachol for 0.5, 1, 2, and 6 h as well as overnight. Time-
dependent change of phospho-p42/44 MAPK and Ras in the presence
of 50 mg/ml of carbachol was detected by immunoblot analysis.
Figure 11. Activation of p42/44 MAPK and Ras proteins with FGF-2
treatment. Activation of p42/44 MAPK and Ras by 50 ng/ml of
FGF-2 in cultured mouse scleral fibroblast cells was detected by
immunoblot analysis. Cultured mouse SF cells were serum starved
for 24 h in DMEM and then incubated with 50 ng/ml of FGF-2 for
0.5, 1, 2, and 6 h as well as overnight. Time-dependent change of
p42/44 MAPK in the presence of 50 ng/ml of FGF-2 was detected.
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1287p42/44 MAPK returned to basal levels (p<0.05, n=4). The
p42/44 MAPK activation patterns for carbachol and FGF-2
were similar (Figure 10 and Figure 11).
Carbachol stimulates EGF-R and TGF-β1 activity: Past study
illustrated that scleral cells are directly responsible for DNA
synthesis  and  extracellular  matrix  synthesis  that  produces
axial elongation [33]. Muscarinic agents may act directly on
sclera fibroblast through the G protein coupled muscarinic
receptor to modulate postnatal eye development. We assume
that the effect of muscarinic antagonists may also be mediated
directly  or  indirectly  by  growth  factors  through  receptor
tyrosine kinases, which would then control sclera fibroblast
activity.  For  these  reasons,  we  focused  on  examining  the
activation of EGF receptor and TGF-β1 in the muscarinic
receptor-mediated responses in SF cells. On stimulation with
0.1, 1, 10, and 100 µM concentrations of carbachol, EGF
receptor, and TGF- β1 activities (Figure 12A,B, respectively)
were increased in a dose-dependent manner. On stimulation
with 0.1, 1, 10, and 100 µM concentrations of atropine, the
EGF receptor and TGF-β1 activities were inhibited in a dose-
dependent manner (p<0.05, n=4).
Muscarinic antagonists modulates fibroblast growth factor-2
(FGF-2)  activity:  In  this  experiment  we  showed  that
muscarinic  agents  modulate  fibroblast  growth  factor
Figure  12.  Muscarinic  agents  and
Growth  factor  activity.  A:  EGF-R
ELISA of mouse scleral fibroblast cell
lysate after 24 h exposure to atropine
and carbachol at 0, 0.1, 1, 10, and 100
µM found a dose-dependent change of
EGF  receptor  in  the  presence  of
muscarinic  agents.  Carbachol
stimulated EGF receptor activation in
the cultured SFs. In contrast, the EGF
receptor  activation  was  inhibited  by
atropine  in  a  dose-dependent  manner
(p<0.01, ANOVA, n=4). B: The results
of  TGF-β1  ELISA  of  mouse  scleral
fibroblast cell lysate after 24 h exposure
to atropine and carbachol at 0, 0.1, 1, 10,
and 100 µM is illustrated on the graph.
Carbachol  stimulated  TGF-β1
activation  in  the  cultured  SFs.  In
contrast,  the  TGF-β1  activation  was
inhibited  by  atropine  in  a  dose-
dependent  manner  (p<0.01,  ANOVA,
n=4).  Data  are  represented  as  mean
±SEM.
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1288expression in these cells. Atropine increased FGF-2 activation
in a dose-dependent manner. In contrast, carbachol decreased
FGF-2  stimulation  in  a  dose-dependent  manner  (Figure
13A,B).  Intraocular  injection  of  FGF-2  can  prevent  axial
elongation induced by form deprivation [34], suggesting that
form deprivation might be associated with a reduction of
FGF-2 or its receptors.
DISCUSSION
The fibroblast is the only cell type present in the collagenous
scleral matrix, which is itself a product of these cells. Studies
on scleral thinning and the involvement of the extracellular
matrix [17] suggest that sclera elongation in experimental
myopia involves more than just the weakening and stretching
of sclera and requires biochemical and molecular changes for
remodeling. The fundamental finding regarding these events
is that atropine can retard myopia progression in humans [5,
35].  As  shown  in  this  study,  atropine  affects  both  the
muscarinic signaling as well as events mediated by growth
factors. As the sclera fibroblast would be one of the first cell
types to be contacted by a topical application of atropine as it
moves into the eye, the mAChRs present in both human and
mouse sclera makes it likely that the SF could be directly
modulated by atropine.
Mouse SFs had higher levels of the M2 and M5 receptor
when compared to other subtypes. It was reported in an earlier
study that the M2 subtype is abundantly expressed in smooth
muscle throughout the gastrointestinal tract [36] and in human
lung fibroblasts [37]. The M5 gene is abundantly expressed in
ocular surface cells [31]. Studies [38] have reported that the
message for M5 predominated in cultured human lens cells
with little or no expression of M1 or M3. In contrast, in native
lens cells, M1 mRNA was in greatest abundance whereas in
HLE-B3 cells [17] and the human brain [39], M3 mRNA was
predominant.
mAChRs are expressed in both neurons and glial cells of
the central nervous system (CNS) and in various peripheral
tissues [40-43]. CNS or neuronal mAChRs regulate a large
number of important central functions including cognitive,
behavioral,  sensory,  motor,  and  autonomic  processes
[44-46]. Studies of the mAChR in non-neural cells show that
they are involved in the regulation of cellular proliferation in
eye growth [47,48], tear fluid production [49], and lens cell
signaling [50]. mAChRs were also shown to be involved in
the  modulation  of  keratinocyte  proliferation  as  well  as
migration, cell-differentiation, and cell-to-cell contact in the
skin  [51].  Carbachol  is  able  to  stimulate  proliferation  in
corneal epithelial cells [31] and human lung fibroblasts [37].
In  the  present  study,  a  significant  increase  in  BrdU
incorporation was found with 50 mg/ml of carbachol in SF.
The effect of carbachol was inhibited by pre-incubating SF
cells with atropine, which is consistent with previous studies
using human conjunctival cells [31]. We further demonstrated
that  M1,  M2,  and  M3  subtype-selective  antagonists  alone
blocked  SF  cell  proliferation.  However,  the  extent  of
inhibition  of  SF  activity  with  the  selective  antagonists  is
different as compared with atropine. M1 subtype-selective
antagonists,  pirenzepine  and  muscarinic  toxin  MT-7,  at
concentration of 1 µM blocked SF cell proliferation by 81%
and 78%, respectively, compared to 71% by atropine at 1 µM.
In contrast, the M2/M4 antagonist (himbacine-86%) and the
M3 subtype-selective antagonist (4-DAMP-90%) effect was
greater than atropine. Our results show that the pan muscarinic
antagonist of atropine was less effective in the inhibition of
SF cell proliferation at a lower concentration. More specific
subtype-selective  antagonists  are  needed  to  study  the
molecular function of each subtype further. Children’s studies
Figure  13.  FGF-2  ELISA  of  mouse
scleral fibroblast cell lysate after 24 h
exposure to atropine and carbachol at
different  concentrations.  Atropine
increased FGF-2 activation in a dose-
dependent  manner.  In  contrast,
carbachol decreased FGF-2 stimulation
in  a  dose-dependent  manner  (p<0.05,
n=4).  Data  are  represented  as  mean
±SEM.
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1289Figure 14. Muscarinic receptor-coupled
signal transduction pathways mediating
MAPK  activity  and  proliferation  in
scleral fibroblasts. Both MAPK activity
and  cell  proliferation  are  strongly
activated  by  cholinergic  (ACh)
stimulation of mAChRs.
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1290with 2% pirenzepine [6] showed that 2% pirenzepine was not
as effective as 1% atropine [35] against myopia progression,
which shows that the M1 receptor is not as critical in myopia
as are some of the other types.
Epidermal growth factor (EGF) and transforming growth
factor-β1 (TGF-β1) have a vital role in cell repair, stimulation
of  cell  proliferation,  cellular  adhesion  regulation,
differentiation,  hematopoiesis,  apoptosis,  tumorogenesis,
migration, and extracellular matrix (ECM) production [52].
EGF functions via the epidermal growth factor receptor (EFG-
R), a member of the ErbB family of receptor tyrosine kinases
[53].  Tyrosine  phosphorylation  of  EGF-R  leads  to  the
activation  of  the  ERK/MAPK  pathways  [54].  EGF-R
functions to transmit intracellular signals leading to regulation
of cell growth. Alterations in the regulation of EGF-R function
and  overexpression  of  receptor  or  ligand  results  in  cell
proliferation.  Anti-myopic  effects  of  atropine  may  be
mediated directly by muscarinic receptor or indirectly through
growth factors such as FGF-2 and TGF-β, which then control
SF  cell  proliferation.  Growth  factors  modulate  cell
proliferation and composition of the extracellular matrix.
Carbachol-stimulated  conjunctival  epithelial  cell
proliferation correlates with the activation of p42/44 MAPK
[27]. Our study showed that 50 mg/ml of carbachol activated
p42/44  MAPK  with  kinetics  similar  to  EGF-R.  This  was
similar to the earlier study reported in corneal epithelial cells
[31]. Carbachol-stimulated activation of p42/44 MAPK has
been observed in goblet cells through increased intracellular
Ca2+ concentration or transactivation of EGF pathways via
phosphorylation of Pyk2 and Src [55,56]. Carbachol-induced
contractions in the urinary bladder are reported to be mediated
by  G-protein  coupled  muscarinic  M3  receptors  [57].  M3
muscarinic receptors also mediate contraction in the guinea
pig taenia cecum [58], and regulation of G protein levels could
be playing a role in controlling muscarinic receptor activity in
vivo [59].
Selected entities from our studies were analyzed with
interacting muscarinic pathways using pathway studio 6.0
(Ariadne Genomics, Rockville, MD; Figure 14) to explore the
underlying intracellular signaling pathways involved in SFs
treated with muscarinic agents. EGF-R is in the upstream, and
all  mAChRs  are  mediated  via  activation  of  the  Ras-Raf-
MAPK cascade. Both MAPK activity and cell proliferation
are strongly activated by cholinergic (ACh) stimulation of
mAChRs. Our data also support a role for G-protein coupled
receptor-signaling pathway, which could be important for the
muscarinic receptor mediated scleral cell proliferation [60].
In  summary,  our  study  showed  the  quantitative
distribution of the five mAChRs in mouse SFs for the first
time and also confirmed the presence of all five mAChRs in
human and mouse SFs. Activation of mAChRs by carbachol
led to increased SF cell proliferation. The mitogenic effect of
carbachol correlated with the activation of p42/44 MAPK.
The SF treated together with antagonists and agonists, the
muscarinic antagonists blocked the agonist’s activation in a
dose-dependent  manner.  Muscarinic  agents  modulate
fibroblast growth factor expression in these cells. Atropine
increased FGF-2 activation in a dose-dependent manner. In
contrast, carbachol decreased FGF-2 stimulation in a dose-
dependent manner. M2 and M5 genes are abundantly expressed
in SFs and should be considered in the future design and
selection of muscarinic receptor agonists or antagonists for
use in topical eye drops.
It is shown that mAChRs mediate proliferation of human
and  mouse  SF,  a  mechanism  possibly  involved  in  scleral
remodeling. Blockade of these receptors might contribute to
long-term beneficial effects of an anti-cholinergic drug in
myopia.
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